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A B S T R A C T
Introduction: Oropouche fever is an under-reported and emerging infectious disease caused by
Oropouche virus (OROV). Its incidence is under-estimated mainly due to clinical similarities with other
endemic arboviral diseases and the lack of specific diagnostic tests. We report the first outbreak of
Oropouche fever in a western region of the Peruvian Amazon in Huanuco, Peru.
Methods: A transversal study was carried out during an outbreak in the western Region of Huanuco, Peru
between January and July of 2016. Blood samples of 268 patients with acute febrile syndrome were
collected and analyzed for OROV via RT- PCR and genetic sequencing.
Results: Of all 268 patients, 46 (17%) cases tested positive for OROV. The most common symptoms
reported were headache with a frequency of 87% (n = 40) followed by myalgia with 76% (n = 35), arthralgia
with 65.2% (n = 30), retro-ocular pain 60.8% (n = 28) and hyporexia with 50% (n = 23). Some patients
showed a clinical presentation suggestive of severe OROV infection, of which 4.3% (n = 2) had low platelet
count, 8.6% (n = 4) had intense abdominal pain, and 2.1% (n = 1) had a presentation with thoracic pain.
Conclusion: This study reports an outbreak of OROV in a region where this virus was not previously
identified. The disease caused by OROV is an emerging, underdiagnosed infection that requires further
research to determine its virulence, pathogenesis, host range and vectors involved in the urban and
sylvatic cycles as well as identifying new genotypes to implement sensitive and specific diagnostic tools
that can be applied to endemic regions.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The Oropouche virus (OROV) is an arbovirus member of the
Peribunyaviridae family and the Orthobunyavirus genus (Briese
et al., 2016), responsible for a febrile syndrome that has affected* Corresponding authors at: Universidad Peruana de Ciencias Aplicadas, Av. San
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).people since its first discovery in 1955 in Trinidad and Tobago
(Anderson et al., 1961). The etiological diagnosis of OROV infection
is challenging due to the clinical similarities with other arboviral
diseases including dengue, chikungunya, zika, and mayaro viruses,
in addition to other pathogens such as Malaria (da Costa et al.,
2017; Alvarez-Falconi and Ríos, 2010; Travassos da Rosa et al.,
2017), and the lack of molecular differential diagnostic methods in
endemic regions. Consequently, the infection caused by OROV is a
disease with an underestimated incidence.
During the past decade, four different genotypes have been
described in more than 30 outbreaks within Central and Southiety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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genotypes has been evidenced and suggested to be due to the
geographic migration of the virus as shown in previous outbreak
reports following the eastern migration of OROV Genotype II virus
(Travassos da Rosa et al., 2017).
Two biological cycles have been described for OROV: sylvatic and
urban. There are reports that pale-throated three-toed sloths
(Bradypus tridactylus) and some primates act as vertebrate hosts
in the rainforest (Pinheiro et al., 1981; Tilston-Lunel et al., 2015;
Nunes et al., 2005). The main vector for sylvatic OROV transmission
has not been identified yet. However, previous studies describe the
isolation of OROV in the vectors Ochlerotatus serratus and
Coquilletidia venezuelensis (Pinheiro et al., 1981; Pinheiro et al.,
2004). The primary vector of OROV in the urban cycle is Culicoides
paraensis but other vectors have also been described, including
Culex p. quinquefasciatus (Travassos da Rosa et al., 2017). Interest-
ingly, with the geographic extension of the virus, as evidenced in
recent outbreaks, possible vectors should not be ruled out.
The febrile syndrome caused by OROV is reported to have an
incubation period of four to eight days (Travassos da Rosa et al.,
2017). The most common symptoms include fever, headache,
myalgia, and arthralgia (Alvarez-Falconi and Ríos, 2010). Addition-
ally some patients may experience gastrointestinal symptoms such
as anorexia, nausea, emesis, diarrhea and epigastric pain (Alvarez-
Falconi and Ríos, 2010). A Rubella-like rash has also been reported
in some outbreaks. Neurological symptoms are uncommon, but
patients with cerebrospinal fluid (CSF) isolation of OROV have
shown symptoms similar to meningitis. Other signs and symptoms
include dizziness, photophobia, retro-orbital pain, (da Costa et al.,
2017; Travassos da Rosa et al., 2017) and gum and vaginal bleeding
in some cases (Alvarez-Falconi and Ríos, 2010). No deaths have
been attributed to OROV infection.
The OROV has characteristics that allow for sustained
transmission in endemic areas (Travassos da Rosa et al., 2017),Figure 1. Location map oand silent circulation has been evidenced in some Amazonian
regions (Briese et al., 2016). Different OROV outbreaks have been
reported in Peru, including San Martin, Cajamarca and Cusco
(Alvarez-Falconi and Ríos, 2010). The virus presents differences in
the replication in vertebrate and invertebrate cells and highlights
the phenomenon of genetic rearrangement (Elliott and Blakqori,
2011). In addition, two variants of the genetically rearranged virus
were identified in Iquitos and Madre de Dios, respectively (Aguilar
et al., 2011; Ladner et al., 2014). These conditions make the spread
of OROV a potential public health issue in the future (Travassos da
Rosa et al., 2017; Weaver and Reisen, 2010).
We report the first outbreak of OROV in Huanuco, which is
located in the western region of the Peruvian Amazon.
Methods
Place of study
This study is descriptive and cross sectional, and was carried out
in the region of Huanuco between January and July 2016. The work
was performed at the primary health care centers that were part of
the Leoncio Prado Health Network of the Ministry of Health of Peru
and in the “Tingo María Contingency Hospital” (Figure 1).
Leoncio Prado province is located in the natural jungle region,
which is part of the Upper Huallaga basin. The relief in this
province is characterized by the presence of physiographic units of
tectonic, orogenic, lithological and climatic factors.
The present physiographic units such as a fluvial valley, hills, an
alluvial valley, mountainous landscape, and a synclinal valley. It
also has a certain ecological homogeneity with diverse tropical
characteristics, predominating the humid montane humid forest
(bh-MBT), tropical humid forest (bh-T) and very humid tropical
premontane (bmh-PT) forest. The annual average of minimum and
maximum temperature is 18.7 C and 30.5 C, respectively Thef the health facilities.
Figure 2. Frequency of patients diagnosed with OROV+ (a). Distribution by gender
of patients (b).
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3472.8 mm with a relative humidity of 77.5% (Gobierno Regional
de Huánuco, 2014).
Study subjects
The inclusion criteria comprised a diagnosis of acute febrile
syndrome, defined as fever higher than 38 C for less than or equal
to 7 days, without an identifiable source of infection and associated
with one or more of the following signs and symptoms: headache,
myalgias, arthralgia, retro-ocular pain, lower back pain, cutaneous
rash, hyporexia, odynophagia, nausea, emesis, abdominal pain,
asthenia, syncope, hypothermia, jaundice. Also, signs that may
suggest severe disease such as epistaxis, bleeding gums, petechiae,
ecchymosis, bloody sputum, hematemesis, thrombocytopenia,
neck rigidity and altered mental state were considered. We
included patients of both genders and without any age restriction.
The exclusion criteria were patients with an incomplete record of
their medical data, patients with an identifiable source of infection,
such as acute upper respiratory tract infections, pneumonia,
urinary tract infections, among others.
Ethics statement
This study was approved by the Research Ethics Board of the
Hospital Regional de Cajamarca, Peru. In addition, we have the
approval of the participating facilities, the Leoncio Prado Health
Network and the Tingo María Hospital. All samples were analyzed
after all participants provided their informed consent before
enrollment or by the parents or childrens caregivers in the case of
underage patients below 18 years of age.
Samples
A total of 268 samples was collected by using Vacuette1 TUBE
Serum Separator Clot Activator (Vacuette, Greiner Bio-One,
Kremsmünster, Austria). The amount of blood extracted was
3 ml. All the samples were stored at 80 C and transported to Lima
(Peru) under standardized frozen conditions for further molecular
analysis.
RNA extraction
RNA extraction was performed following the manufacturer’s
instruction of High Pure RNA Isolation Kit (Roche Applied Science,
Mannheim, Germany) using 200 ml of the samples. Viral RNA
obtained after extraction was eluted in 100 ml of nuclease free
water and then processed or stored at 20 C until use.
RT-PCR amplification for detection of OROV
For the reverse transcription (RT), a 20 ml mixture was prepared
to containing 5 ml of RNA extracts. The transcriptor High Fidelity
cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany)
was used according to the manufacturer’s instructions.
300 bp fragments of the S segment of OROV were amplified, the
primers BUN-S 50-AGT AGT GTG CTC CAC-30 and BUN-C 50-AGT AGT
ATA CTC CAC AGT AGT ATA CTC CAC -30, BS-S 50- AGT AGT ATA CTC
CAC-30 and BS-C 50-TGA ACC CTA TGC ATC T-30 were described by
Moreli et al. (2002). Polymerase chain reaction was performed
with 5 mL of template DNA and FastStar TAq DNA Polymerase
dNTPack (Roche Applied Science, Mannheim, Germany). Amplifi-
cations started with an initial incubation at 95 C for 2 min,
followed by 40 cycles of 95 C for 1 min, 55 C for 1 min, and 72 C
for 45 s, with a final extension at 72 C for 5 min. Amplicons were
detected as 300 bp bands after gel electrophoresis and nucleic acidstaining (SyberGreen, Promega). PCR products were purified using
SpinPrepTM Gel DNA Kit, San Diego, USA and sequenced by Sanger
method (Macrogen, Seoul, South-Korea).
Statistical analysis
Qualitative variables were reported as frequencies in percent-
age. Fisher test (F-test) was used to determine the significative
differences with a p-value 0.05. The correlation matrix was made
to analyze the association of signs and symptoms. All analyses
were processed with the Minitab Inc. software version 18.1 (USA).
The graphic representation of the data was made with the
OriginPro v10 software (OriginLab Corp., USA).
Results
Demographic characteristics
A total of 46 out of 268 samples was positive for OROV. Hence,
the rate of OROV infection was 17.2% (Figure 2a). This frequency is
significantly greater (p < 0.004, F-test) than the hypothetical
frequency established at 8.6% in studies conducted in the endemic
area of OROV (Alva-Urcia et al., 2017). The diagnosis of OROV was
not influenced by the gender of the patients (Figure 2b). The ages in
the studied population were adjusted to a Gaussian model with an
average age of 20.8  15.7 years (average  standard deviation),
and similarly the population with OROV- diagnosis showed an
average of 22.3  15.6 years. However, the population with the
OROV + diagnosis showed a clear deviation towards younger ages,
with an average of 15.2  9.8 years (Figure 3). For a more detailed
Figure 3. Distribution of the ages of patients.
Table 1
Demographic characteristics of the studied population ORO + and OROV.
Age Total of cases OROV-positive OROV-negative F-test
(Years) (N) (%) (N) (%) (N) (%) (p-Value)
<5 15 5.6 4 8.7 11 5.0 0.0270
5–11 38 14.2 8 17.3 30 13.5 <0.0001
12–17 40 14.9 13 28.2 27 12.2 0.0030
18–39 123 45.9 15 32.6 108 48.6 <0.0001
40–59 40 14.9 5 10.9 35 15.8 <0.0001
>60 12 4.5 1 2.1 11 5.0 <0.0001
Total 268 100.0 46 100.0 222 100.0
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The higher frequencies of positive cases were found in the age
groups of 18–39 and 12–17 with 32.6%, 28.2% respectively.
Significant differences were found between the frequencies of
the positive and negative cases in all age groups (Table 1).
Clinical presentation
Among patients molecularly diagnosed with OROV infection,
the most common symptom reported was headache with a
frequency of 87.0% (n = 40) followed by myalgia with 76.1% (n = 35),
arthralgia with 65.2% (n = 30), retro-ocular pain 60.9% (n = 28) and
hyporexia with 50.0% (n = 23) of the patients (Table 2).
Some patients showed a clinical presentation suggestive of
severe OROV infection, of which 4.3% (n = 2) had low platelet count,
8.6% (n = 4) had intense abdominal pain, 2.2% (n = 1) had thoracic
pain, 2.2% (n = 1) showed gynecological bleeding and 2.2% (n = 1)
had hematemesis. None of the patients in this outbreak reported
neurologic symptoms (Table 2).
Acorrelationanalysisof theclinicalsignsandsymptomsof patients
with OROV + diagnoses was made according to the age of the patients(Figure 4). A close association between febrile syndrome and the
diagnosis of OROV + was observed (r = 100.0 %). This association is
clearly detected in patients aged 5–59 years. However, the groups of
extreme ages, less than 5 years and older than 60 years show varied
signs and symptoms that are not clearly associated with febrile
syndrome (r with values of 78.8% and 86.1%, respectively); this may
correspond to an ambiguity of the patient’s age.
Discussion
We report the first OROV outbreak registered in the Province of
Leoncio Prado. We were able to confirm 46 positive cases of
Oropouche virus infection using molecular diagnostic methods.
Along with other recently reported outbreaks in Cusco, Madre
de Dios (World Health Organization, 2016), Venezuela (Navarro
et al., 2016) and the first reported case of OROV outside the
Amazonian region (de Souza Luna et al., 2017), this report may
indicate that the virus is re-emerging and expanding. This
expansion may be due to recent local ecosystem changes that
could affect the known transmission cycle of the disease by
favoring the migration of the vectors and involved hosts (Khalil
et al., 2016). A similar hypothesis was proposed recently in an
outbreak in the region of San Martin due to the construction of a
highway (Alvarez-Falconi and Ríos, 2010) and in Cusco due to
vegetation loss (Romero-Alvarez and Escobar, 2017). In the location
of this study, there is evidence of an increase in agricultural
activities, highway and road development, as well as bridge
constructions, that may affect the ecosystem either due to
population migration, vegetation loss, or redistribution of wild
reservoirs and vectors (Khalil et al., 2016).
The geographic expansion of OROV could be explained by
climate change as temperature and precipitation anomalies that
have been described to alter patterns of arboviral transmission
cycles (Gould et al., 2017; Agarwal et al., 2017). In the case of
Culicoides; increasing temperatures favor oogenesis and shorten
periods of mature development (Purse et al., 2015). In this context,
during the study period of this outbreak, the National Service of
Meteorology and Hydrology of Peru (SENHAMI) reported a
temperature anomaly of 2.0 C above the maximum temperature
and 0.4 C above the minimum temperature in the high and low
altitude Amazonian regions of Huanuco (Boletín Hidrometeor-
ológico Regional de Huánuco, 2017).
Several studies consider arboviruses as a serious threat to world
public health, especially in tropical and subtropical countries in
which factors such as deforestation, migration, lack of urban
planning and poor sanitation in the context of change global
climate, facilitate the expansion of vectors into new areas and
exponentially increase the population at risk (Mota et al., 2016).
The epidemic potential of arboviruses has been reported by the
World Health Organization. This potential is considered both
endemic and Dengue virus (DENV), in addition to recently
expanded viruses or those recently introduced in Latin American
countries (Brazil and Peru among others), such as the Mayaro virus
(MAYV), the virus Chikungunya (CHIKV) and the Zika virus (ZIKV)
(Mota et al., 2016; Figueiredo, 2015). Our study reinforces the idea
of considering arboviruses as a threat while we report the presence
of OROV in an area where it has not been previously described. This
future description may imply the appearance of OROV epidemics
both in regions where it is already present and in regions where it
can be expanded.
Patients may be asymptomatic, develop an isolated febrile
episode, or develop a febrile illness associated with skeletal,
dermatological and neurological or hematological complications in
severe cases (Donalisio et al., 2017). As previously mentioned, the
most common signs or symptoms in the clinical presentation of
OROV infection include headache, myalgia, and arthralgias
Table 2
Clinical presentation of patients with Oropouche virus infection.
Sign or symptom Total cases n = 268
(%)
OROV+ N = 46
(%)
Positive cases for OROV
<5 years n = 4
(%)
5–11 years n = 8
(%)
12–17 years n = 13
(%)
18–39 years n = 15
(%)
40–59 years n = 5
(%)
60 years n = 1
(%)
Fever 268 (100.0) 46 (100.0) 4 (100.0) 8 (100.0) 13 (100.0) 15 (100.0) 5 (100.0) 1 (100.0)
Headache 249 (92.9) 40 (86.9) 3 (75.0) 6 (75.0) 12 (92.3) 13 (86.7) 5 (100.0) 1 (100.0)
Myalgias 231 (86.2) 35 (76.1) 1 (25.0) 8 (100.0) 9 (69.2) 12 (80.0) 4 (80.0) 1 (100.0)
Arthralgias 228 (85.1) 30 (65.2) 2 (50.0) 5 (62.5) 6 (46.2) 12 (80.0) 4 (80.0) 1 (100.0)
Retro-ocular pain 174 (64.9) 28 (60.9) 2 (50.0) 5 (62.5) 6 (46.2) 11 (73.3) 3 (60.0) 1 (100.0)
Hyporexia 145 (50.1) 23 (50.0) 4 (100.0) 2 (25.0) 6 (46.2) 7 (46.7) 3 (60.0) 1 (100.0)
Nausea/emesis 132 (49.3) 22 (47.8) 3 (75.0) 3 (37.5) 7 (53.8) 5 (33.3) 4 (80.0) 0 (0.00)
Lumbar pain 127 (47.4) 16 (34.8) 0 (0.0) 2 (25.0) 5 (38.5) 5 (33.3) 3 (60.0) 1 (100.0)
Odinophagya 80 (29.9) 16 (34.8) 3 (75.0) 3 (37.5) 5 (38.5) 4 (26.7) 0 (0.0) 1 (100.0)
Cutaneous rash 71 (26.5) 15 (32.6) 2 (50.0) 2 (25.0) 5 (38.5) 4 (26.7) 1 (20.0) 1 (100.0)
Abdominal pain 12 (4.5) 4 (8.7) 1 (25.0) 0 (0.0) 1 (7.7) 1 (6.7) 1 (20.0) 0 (0.0)
Platelet decrease 8 (3.0) 2 (4.3) 0 (0.0) 0 (0.0) 2 (15.4) 0 (0.0) 0 (0.0) 0 (0.0)
Hematemesis 6 (2.2) 1 (2.2) 0 (0.0) 0 (0.0) 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0)
Epistaxis 4 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Petechiae 4 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Bleeding gums 3 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Bloody sputum 3 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Thoracic pain 3 (1.1) 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.7) 0 (0.0) 0 (0.0)
Melena 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Gynecological
bleeding
2 (0.7) 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0)
Diuresis reduction 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Jaundice 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hematocrit
increase
2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Altered mental
state
2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ecchymosis 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Persistent
vomiting
1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hypothermia 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Lipothymia 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hypotension 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Figure 4. Pearson correlation of the clinical signs and symptoms of patients with OROV + diagnosis was made according to the age. The dispersion matrix presents ellipses at
95% confidence in the lower symmetric part that represent the values of the Pearson correlation coefficient (r) and its associated p value in the upper symmetric part of the
matrix.
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this outbreak, the most common symptoms were fever at
presentation with 100.0%, followed by headache in 92.9%, myalgia
in 86.2%, arthralgias in 85.1%, retro-ocular pain in 64.9% and
hyporexia in 50.1% of patients. However, this study did not considerrecurrent symptoms because the patients were not followed up, a
finding similar to the outbreak registered in Begazan, San Martin
(Alvarez-Falconi and Ríos, 2010).
As a member of Orthobunyavirus, OROV is able to interchange
segments of RNA with other strains through genetic reassortment,
144 W. Silva-Caso et al. / International Journal of Infectious Diseases 83 (2019) 139–144particularly with segments S and L, allowing the incorporation of
genes that may develop novel virulent viral strains that may lead to
new outbreaks, such as the recently reported IQTV and MDDV
(Aguilar et al., 2011; Ladner et al., 2014). This could imply that
OROV increases its virulence and pathogenicity, increasing its
capacity to generate epidemics and severe disease. These relevant
strains were shown to spread to brain and the liver, which may
explain the more severe clinical presentation seen in some patients
(Travassos da Rosa et al., 2017). Central nervous system symptoms
have also been reported among patients with cerebrospinal fluid
(CSF) isolates of OROV (Alvarez-Falconi and Ríos, 2010; Travassos
da Rosa et al., 2017). During this outbreak, 4.3% had low platelet
count, 8.6% had abdominal pain, one patient had hematemesis, one
patient had gynecological bleeding, and none had symptomatology
that suggested central nervous system involvement.
Conclusions
The disease caused by the OROV is an emerging, under-
diagnosed infection that requires ongoing research to determine
its virulence, pathogenesis, host range and most common vectors.
Furthermore, the identification of new genotypes could aid the
development of more sensitive diagnostic tools that could be used
in endemic regions. This study reports an outbreak of OROV in
Huanuco for the first time. Even though there have not been any
mortalities reported since the initial identification of OROV,
recent outbreaks show a pattern that highlights the emerging
potential of the virus and demonstrates the need to implement
new public health policies prioritizing local epidemiological
surveillance.
Limitations
On the basis of genetic and antigenic analyses, other studies
have detected several reordered viruses involving OROV and other
unknown Simbu serogroup viruses, which for the time being
constitutes a limitation in our work and encourages us to carry out
further investigations.
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